Lianhua Qingwen and other "three medicines" add new coronary pneumonia indication experts reminded not to eat if not sick
The term "three medicines and three prescriptions" originated from a press conference held by the State Council Information Office on March 23, where "three medicines" refers to Lianhua Qingwen Capsules (Granules), Jinhua Qinggan Granules and Xuebijing Injection.
Recently, these three drugs have become the first batch of drugs approved for new indications of new coronary pneumonia in China. Once the relevant announcement was issued, it attracted public attention.
This is not the first time three drugs have received attention. As early as in early February, they were included in the "New Coronavirus Infection Pneumonia Diagnosis and Treatment Program" (Trial Version 4). Since then, they have been included in multiple versions of the program and clinical diagnosis and treatment of patients with new coronary pneumonia.
The Lianhua Qingwen in the "Three Medicines" was developed for the treatment of "SARS", while the Jinhua Qinggan Granules were developed in response to the 2009 H1N1 influenza.
In the prevention and control of the new coronary pneumonia epidemic, the "three drugs" played an important role, and as a result, they became tight, sales increased significantly, and even shortages occurred.
An expert in traditional Chinese medicine said in an interview with Peng Mei News (www.thepaper.cn) on April 17 that although the three drugs can treat new coronary pneumonia, the corresponding symptoms are different, and they should be treated as symptomatically. Citizens who have no symptoms and are not infected with new coronary pneumonia should not take these drugs, nor can they "prevent" new coronary pneumonia by taking these three "treatment" drugs. Three new drugs have been approved for new indications for coronary pneumonia, which will provide a boost for Chinese medicine to go global. However, if Chinese medicine is to be truly internationally recognized, there is still a long way to go.
Three Chinese patent medicines approved to increase the indication of new coronary pneumonia
"The important role played by the" three drugs "in this epidemic and the good evidence obtained, the State Food and Drug Administration has approved the treatment of new coronary pneumonia into the new indications of the three drugs." News on the afternoon of April 14 At the press conference, Li Yu, director of the Science and Technology Department of the State Administration of Traditional Chinese Medicine, said so.
The relevant approval documents issued by the State Drug Administration respectively state:
Approval of Lianhua Qingwen Capsules (Particles) Instructions [Functional Indications] Item added "Routine treatment of new coronavirus pneumonia, can be used for fever, cough and fatigue caused by light and common types" [Usage and Dosage] Item added "new crown Viral pneumonia light and ordinary treatment course 7-10 days. "
Approval of Xuebijing Injection Instructions [Functional Indications] item added "can be used for new coronavirus pneumonia severe and critical systemic inflammatory response syndrome or / and multiple organ failure." [Usage and Dosage] item added "used New coronavirus pneumonia: 100ml diluted with 0.9% sodium chloride injection 250ml, twice a day. "
In addition to the original approved content, the "Functional Indications" item in the approved Jinhua Qinggan Granules was added "In the routine treatment of new coronavirus pneumonia, it can be used for fever, cough, and fatigue caused by light and common types." [Usage and Dosage] In addition to the original approved content, add "new coronavirus pneumonia light and ordinary type: 1 to 2 bags at a time, 3 times a day. The course of treatment is 5 to 7 days."
The surging news inquiry manual found that the functions of the three Chinese patent medicines all include "clearing heat and detoxification", which is suitable for fever symptoms. Among them, Lianhua Qingwen Capsule also treats "coldness, muscle soreness, nasal congestion, runny nose, cough", etc .; Xuebijing Injection also treats wheezing, palpitations, infection-induced systemic inflammation, etc .; the functions of Jinhua Qinggan Granules also include "Red and sore throat, stuffy nose, runny nose, thirst" and so on.
Information from the State Administration of Drug Administration shows that Lianhua Qingwen Capsules, Granules and Tablets belong to Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as Yiling Pharmaceutical) and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. Exclusive patented product; Xuebijing injection is produced by Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter: Hongri Pharmaceutical); Jinhua Qinggan Granule is Juxiechang (Beijing), a subsidiary of Beijing Yushengtang Sinopharm Holding Co., Ltd. Exclusive product of the pharmaceutical industry.
Surging News noted that after the approved news was announced, as of April 17, Yiling Pharmaceuticals and Hongri Pharmaceuticals, which are listed companies, had experienced three consecutive days of daily limit.
Lianhua Qingwen "born because of SARS"
Lianhua Qingwen was developed for the treatment of SARS.
A department head of Yiling Pharmaceutical Company told Peng Mei News on April 15 that the SARS epidemic broke out in 2003, and Wu Yiling, an academician of the Chinese Academy of Engineering and founder of Yiling Pharmaceuticals, started research and development of symptomatic new drugs.
According to the person in charge, Lianhua Qingwen Capsules and Granules gathered the three dynasty prescriptions of Zhang Zhongjing's "Ma Xing Shi Gan Tang" in the Han Dynasty, "Rhubarb" which can be used to cure epidemic diseases in Wu Dynasty in the Ming Dynasty, and "Yinqiao San" in Wu Jutong in the Qing Dynasty It is developed by combining the effective traditional Chinese medicine found in modern scientific research with anti-virus, anti-inflammatory, cough, phlegm and immunity enhancement. Related experiments confirmed that Lianhua Qingwen Capsule has an inhibitory effect on SARS virus. Soon afterwards, Lianhua Qingwen Capsule entered the green channel for rapid approval of new anti-SARS drugs.
After the SARS epidemic ended, Lianhua Qingwen turned to the battlefield against influenza.
The person in charge said that in the view of Chinese medicine, influenza and "SARS" belong to the category of "external fever", which is what the Chinese medicine called "the plague". Experiments by the Chinese Academy of Chinese Medical Sciences have confirmed that Lianhua Qingwen can inhibit influenza virus H3N2, parainfluenza virus type I, respiratory syncytial virus, and adenovirus.
In May 2004, Lianhua Qingwen Capsule passed the review of the State Drug Administration and other departments, obtained a new drug certificate and production approval, and became a new member of China's anti-influenza drugs.
Surging News found that Lianhua Qingwen Capsules (granules) have been included in the national diagnosis and treatment program more than 20 times as a recommended medication, including the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Program" (trial fourth version to seventh) Version).
Similar to Lianhuaqingwen, Jinhuaqinggan granules are also "born due to disease".
According to Caixin.com, in April 2009, influenza A H1N1 from North America spread. In June, the Beijing Municipal Government launched a scientific and technological breakthrough in the treatment of the flu with traditional Chinese medicine. In December of that year, the Beijing Municipal Government Information Office announced "an effective method for the treatment of Influenza A H1N1 flu 'Jinhua Qinggan Fang'", which subsequently evolved into today's "Jinhua Qinggan Granule".
"Three drugs" sales may grow again
Because of the extraordinary performance in the clinical treatment of new coronary pneumonia, coupled with the affirmation of experts, these three drugs have an effect on the treatment of new coronary pneumonia, so they have become "tight drugs" this year.
"Tight" brings intuitive sales.
"January to March 2020, the net profit increased by 50% to 60% over the same period of the previous year." On March 31, Yiling Pharmaceuticals disclosed on the Shenzhen Stock Exchange's official website that the performance forecast for the first quarter of 2020 showed that The net profit of Huaqing plague products increased significantly compared with the same period last year.
According to the aforementioned person in charge of the Ling pharmaceutical department, in order to ensure supply, the company has adjusted its production plan urgently according to market demand since late January, and used all production lines for 24 hours to produce Lianhua Qingwen products. The maximum daily production capacity is 50 million capsules. , More than 2 million bags of granules, other products temporarily rely on the company's finished product inventory and commercial channel inventory to meet market supply.
The person in charge said that after nearly 40 days of "production rush action", the current shortage of terminals in the Lianhua Qingwen market has eased. The current main bottleneck in production capacity is the extraction capacity of medicinal materials. The follow-up company plans to invest in a production base in Hengshui City, Hebei Province. The first phase will give priority to building an extraction workshop to alleviate the company's current bottleneck in extraction capacity.
In addition to being approved for the addition of new coronary pneumonia indications, the State Drug Administration issued an announcement on April 8 that in order to meet the needs of new coronary pneumonia epidemic prevention and control, Jinhua Qinggan granules will be converted from prescription drugs to class A over-the-counter drugs.
This means that Jinhua Qinggan granules can be entered into pharmacies for retailing just like Lianhua Qingwen capsules; Lianhua Qingwen granules (tablets) and Xuebijing are prescription drugs, which need to be purchased with a doctor's prescription or medical order.
Hongri Pharmaceuticals ’April 1st 2020 performance announcement disclosed on April 9 also stated that the company ’s main product, Xuebijing injection, was used as an epidemic medicine, and its sales volume increased significantly over the same period of the previous year.
Surging News noted that as of the close of April 14, Ling Pharmaceutical (stock code: 002603) had a daily limit, and its share price was 31.32 yuan; as of the close of the 15th, the price was 34.45 yuan, which was also in the daily limit. Yiling Pharmaceutical achieved three consecutive daily limit.
At the same time, on April 14th, Red Sun Pharmaceutical (stock code: 300026) quoted 5.40 yuan, and the stock price rose by 3.85%. This year, the cumulative increase of the stock has reached 53.85%, and it has also been harvested by April 17. Daily limit for three consecutive days.
Expert: There is still a long way to go for Chinese medicine to be recognized internationally
Liu Baoyan, former executive vice president of the Chinese Academy of Chinese Medical Sciences and director of the Chinese Medicine Data Center, told Peng Mei News on April 17 that during the epidemic, he and Wuhan first-line researchers collaborated to take patients with new coronary pneumonia in Wuchang District as the sample and rely on the Internet to master new coronary pneumonia patients Medications. The data shows that among the medicines taken by patients, Chinese patent medicines take the first place, accounting for 35.99%.
Liu Baoyan introduced that three new drug-induced bitter colds, "clearing heat and detoxifying", were approved for the new indication of coronary artery pneumonia. Among them, Jinhua Qinggan granules can treat patients with fever faster than other drugs, which is mainly suitable for early and mild patients; Lianhua Qingwen can also treat cough and relieve lung inflammation; blood must be clean The injection can also protect the patient's organs from damage and can be used for severe and critically ill patients.
"It is a three-way drug. Any medicine has indications. This is especially true of traditional Chinese medicine. Different people may have different reactions with the same medicine." Liu Baoyan said that although all three medicines can treat new coronary pneumonia, they also need to Try to use symptomatic medicine as much as possible.
In a previous interview, the surging news reporter also learned that some citizens did not contract new coronary pneumonia, but thought that drugs such as Lianhua Qingwen could prevent infection, so they bought it for themselves.
In this regard, Liu Baoyan particularly reminded that citizens who have no symptoms and are not infected with new coronary pneumonia should not take these drugs, nor can they "prevent" new coronary pneumonia by taking three "treatment" drugs.
"If you take these medicines without getting sick, it will damage the stomach and the body's yang." He suggested that if the citizens are worried about infection, they can take medicines that strengthen the body and strengthen their resistance according to their physical characteristics, such as spleen and stomach. Bad, it is necessary to symptomatic use of drugs to regulate the spleen and stomach. In addition, sleeping on time, eating regularly, and exercising regularly can all enhance the body's resistance. "You don't have to take medicine."
New Coronary Pneumonia is spreading in many countries around the world. These three drugs have been approved for new indications for New Coronary Pneumonia, which also provides a thrust for Chinese medicine to go global. But in Liu Baoyan's view, there is still a long way to go before Chinese medicine can be truly recognized internationally. He said frankly that some countries have strict approvals for medicines. If they want to enter the shelves of medicines in other countries, they must first obtain approval. At the same time, foreign medicines are mostly single-component medicines, while traditional Chinese medicines are multi-component medicines. Foreigners generally worry about the side effects of traditional Chinese medicines. In addition, the citizens of some countries have relatively large deviations in the understanding of Chinese medicine, which has also caused Chinese medicine to be blocked in the world.
Surging News reporter Xue Shasha